WATERTOWN, Mass., May 21, 2025 - Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company, has announced a definitive merger agreement with Sanofi $(SNY)$. Under the terms of the agreement, Sanofi will acquire all outstanding common shares of Vigil for $8.00 per share in cash, amounting to an equity value of approximately $470 million. Additionally, Vigil's shareholders will receive a non-tradeable contingent value right $(CVR)$ entitling them to an additional $2.00 per share in cash, contingent on the first commercial sale of VG-3927. The acquisition is anticipated to bolster Sanofi's neurology focus, particularly in advancing the TREM2 agonist program, including VG-3927, a Phase 2-ready candidate for Alzheimer's treatment. The companies expect the transaction to close in the third quarter of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。